Public-Private Roles in the Pharmaceutical Sector - Implications for Equitable Access and Rational Drug Use - Health Economics and Drugs Series, No. 005
(1997; 115 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentAuthors
Afficher le documentAcknowledgements
Afficher le documentAbbreviations and Acronyms
Afficher le documentExecutive summary
Ouvrir ce répertoire et afficher son contenu1. Public and private roles in the pharmaceutical sector
Ouvrir ce répertoire et afficher son contenu2. Pharmaceutical markets: structure and performance
Ouvrir ce répertoire et afficher son contenu3. Essential state responsibilities
Fermer ce répertoire4. The public-private mix in drug markets: a global picture1
Afficher le document4.1 Production
Afficher le document4.2 National expenditure
Afficher le document4.3 Drug distribution systems
Afficher le document4.4 Household expenditures and sources of drugs
Afficher le document4.5 Summary points
Ouvrir ce répertoire et afficher son contenu5. Market mechanisms in public drug supply
Ouvrir ce répertoire et afficher son contenu6. Promoting public health needs through the private sector
Ouvrir ce répertoire et afficher son contenu7. Pharmaceutical production and public-private roles
Ouvrir ce répertoire et afficher son contenu8. Capacity-building and the process of change
Ouvrir ce répertoire et afficher son contenu9. Managing public-private roles
Afficher le documentReferences
Afficher le documentGlossary
Afficher le documentBack Cover
 

4.4 Household expenditures and sources of drugs

Data on household expenditure complement those from other sources. Such data provide insights into both utilization patterns and the level of private out-of-pocket expenditure.

At the individual and household level, drugs represent the major out-of-pocket expenditure on health. A survey from Mali found that 80% of household expenditure on health was for modern drugs, 13% was for traditional medicine, 5% was for provider fees, and 2% was for transportation costs [35]. In Côte d'Ivoire and Pakistan more than 90% of household health expenditure was related to drugs [136]. Drugs or traditional products represent 62% of financial costs per treatment episode in Burkina Faso, with 17% for provider fees and 21% for transport and other living expenses incurred while seeking care [39].

Among 14 countries of Latin America and the Caribbean, drugs represented 35% of direct private expenditures on health. Figures ranged from slightly under 15% in the Cayman Islands and Uruguay to 44% in Peru, 45% in Guatemala, 46% in Colombia and 47% in El Salvador [94].

Household expenditure on drugs is closely tied to household income. In Ghana, for example, annual per capita drug expenditure varied from US$ 1.45 per person in the lowest-income households to $ 3.32 in middle-income households to $ 8.50 in the highest-income households [137].

Self-medication with privately purchased drugs often represents the most common treatment after home remedies. Household surveys indicate that drugs purchased from local drug sellers or pharmacies are used to treat approximately 53% of illness episodes in Burkina Faso (Figure 2). In an urban setting in Sri Lanka nearly 64% of the first actions taken by households in treating an illness were self-medication with western or traditional drugs (Figure 3). Studies on general and low-income populations in Kenya [97], Nepal [73], Rwanda [33], Thailand [108] and elsewhere [1,55] show similar high rates of medication with drugs acquired in the private sector. Even for potentially life-threatening illnesses such as malaria, self-medication through privately purchased drugs is common in both Africa and Asia [39,86].

Thus, at the household level as well as at national level, private purchase of drugs plays a major role in many countries, even for low-income populations.


Figure 2. Percentage distribution of household health-care-seeking behaviour, Burkina Faso [104]


Figure 3. Source of care for acute illnesses in Sri Lanka [112]

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013